Member Info for Mikemine

I'll probably have to go to whoever runs AIM over this. It's giving AIM a bad name for being negative. If anybody else investing elsewhere has the same experience can they let me know.

Those first 2 trades look like buys to me. This has been going on a lot and gives AIM a negative bias as well misleading investors. I've contacted LSE about this but might have to go to AIM itself.

You are probably right K but I just had to do it.

I've written to LSE pointing out the large scale misrepresentation of trading data and asking them to rectify it. It must be a computer glitch but it must affect sentiment about the underlying share/company including VRCI. It's hard enough making money on AIM without this negative bias being built in.

I'd like to know who they will recruit in the future. The next fundraiser is all about sales and marketing Barrington said so lets get on with it.

It's not just here K. I made 2 largish buys of RNLX a few days ago and they were both classed as sells. There were a few other trades at almost the same price so I took them to be buys as well. If this is widespread over AIM it's no wonder it's got a bad reputation for being negative. It's not a small thing as it can, and probably does, influence sentiment about stocks.

I've just done a dummy buy and the quote to buy was 0.454p

I think you've summed up the position very well. The only thing to add is the tests are trying to progress in an established market rather than trying to carve out a demand. The clinicians want Tutivia and Clavara so watch this space.

It's worth noting that CareDx has a competing test which is well established in the transplant field but it is reactive rather than proactive so of less value to clinicians. Nevertheless, from memory, it brings in either $200 mn or $400 mn annually so thats the market at the moment. It could be much more as the testing protocol and prices are different. If other sales staff from CareDx join Verici then Tutivia will fly.

Well researched Karlonwise and thanks for sharing.

Well researched. Don't know much about Gilliard, to be honest I know nothing about him, but i trust Barrington to run the company well and i'm not surprised she has gone down this route. Barrington has been in this field for over 20 years and it's a small field so she would have developed a huge amount of knowledge about people in it. She wants to recruit more sales people so keep an eye on who she goes for.

If Gilliard worked for CareDX he would know the score so we might ask ourselves why he has chosen to come from a big company to a tiddler like Verici. He must think that Tutivia can fly and, as you say, he has the reach to make that happen. As Barrington has said this is going to be an exciting year for Verici.

If Karlvonwise is correct it looks like someone is trading lots of 1 share sells, presumably to lower the SP. It's been going on for 3 sessions so far.

Does that mean someone is trying to lower the price?

Will they run out of cash soon?

4 trades of 1 share each at the same price. What's that all about?

Take no notice of the RNSs concerning UBS. Over on RENX they were announcing large percentage holdings and then saying they went down to zero in a matter of days, just like they've done here. This backwards and forwards went on for weeks. It bore no relationship to trades and nobody could understand what UBS was doing. Looks like it's started here so best to ignore it.

Worry not.

https://www.greo.ca/Modules/EvidenceCentre/files/Capacci%20et%20al%20(2017)_Are%20consumers%20more%20willing%20to%20invest%20in%20luck_final.pdf

Well, they certainly won't do European expansion on their own. They are going for CE marking in preparation for Europe and thats not because they have nothing else better to do. Do they have a partner lined up I wonder?

Not uncommon Karlvonwise. I bought in 2 trances in another company and they both showed as sells. It happens all the time. I was wondering if the categorisation of sell/buy is adjusted according to what way the MMs want the SP to go and justify their pricing.

I don't know either SB but McCullogh is good at doing deals regardless of what anybody thinks of RENX overall so anything could happen. I'd love to know what happened to the Tempus deal but that put a squib under the SP when it was announced so who knows? If a big company like Tempus put their weight behind the test then it could really fly. I reckon the test is really needed so one way or another it should succeed. We can only wait and see.

Judging by how my 2 buys were classified today as sells, I would say that any trade around the 1.80 mark are buys regardless of how they are reported here. Most misleading for people that just glance at the trades.